Acela CBD

Acela Biomedical is an existing Hemp grower, distributor, processor, extractor, and retailor specializing in CBD Oil Production with over two million plants in the ground in Kentucky. Its processing facility is currently in operation. CBD Hemp Cultivation and CBD Oil Production is a specialized high value agriculture category with more in common horticulture than traditional industrial hemp (fiber and oilseed types). Growing industrial hemp for CBD oil production is approached as a medicinal crop, and grown to suit the requirements of processors and buyers. Acela is building a strong foundation in Kentucky hemp cultivation, production, and processing to deliver consistently higher growth and higher value for our shareholders. Bringing production online at our Kentucky hemp processing plant will represent the Company's latest and most significant milestone toward that objective. Acela Biomedical will continue as a Kentucky Corporation operating as subsidiary of Cardiff Lexington. "We are excited to join forces with Andrew Culbertson and his exceptional team," stated Alex H. Cunningham, Cardiff Lexington CEO. "Andrew and his team will continue to operate and lead Acela Biomedical growth and expansion; our partnership will accelerate that growth and allow Acela to greatly expand capacity and develop both new products and blaze into new endeavors." Andrew Culbertson, Founder of Acela Biomedical responded: "We have established deep roots within the Hemp Industry in Kentucky and are committed to supporting our farmers in Kentucky, Ohio, and Tennessee. This new partnership brings Acela the resources and horsepower for us to make a significant positive impact in Kentucky's Hemp Industry and affords us the capability to expand our operations in Ohio, Tennessee, and West Virginia. We too are excited that with our alliance with Cardiff Lexington's to be able to implement many strategies formulated over the past four years." Cardiff Lexington's business model targets acquisition of middle market private niche companies both mature, and, second stage with high growth potential. The Cardiff Lexington umbrella enables business owners to exit personal equity and to take advantage of the capitalization power of a public company without losing independent management control. Fundamental to the Cardiff Lexington strategy, acquisitions become standalone autonomous subsidiaries gaining advantage of the power of a public company. Owners gain liquidity, diversification, pooled resources, leverage value, and mitigated risk. As a Cardiff Lexington subsidiary these companies gain both the enhanced ability to raise money for operations or expansion while also establishing a longer-term equity exit strategy. For Investors, Cardiff Lexington seeks to aggressively grow and hold assets that create a diversified lower risk environment that over the long term protects and safely enhances investment through a diversified continually growing niche holding company.